Last reviewed · How we verify
NI-071
NI-071 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system.
NI-071 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system. Used for Cognitive impairment associated with schizophrenia.
At a glance
| Generic name | NI-071 |
|---|---|
| Sponsor | Nichi-Iko Pharmaceutical Co., Ltd. |
| Drug class | Phosphodiesterase 9 (PDE9) inhibitor |
| Target | PDE9 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PDE9, NI-071 prevents the breakdown of cyclic GMP, leading to enhanced intracellular signaling that may improve cognitive function and neuroplasticity. This mechanism is being investigated for neurodegenerative and cognitive disorders where PDE9 inhibition may provide neuroprotective or cognitive-enhancing effects.
Approved indications
- Cognitive impairment associated with schizophrenia
Common side effects
Key clinical trials
- A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE) (PHASE3)
- A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (PHASE3)
- Pharmacokinetics Study of NI-071 (PHASE1)
- Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |